{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["51(4)"],"submitter":["Pilgram L"],"funding":["Charité - Universitätsmedizin Berlin"],"pubmed_abstract":["<h4>Objectives</h4>The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation.<h4>Methods</h4>SARS-CoV-2 infected patients between January 2020 and December 2021 treated with RDV were matched 1:1 to controls considering sociodemographics, comorbidities and clinical status. Multiple imputations were used to account for missing data. Effects on fatal outcome were estimated using uni- and multivariable Cox regression models.<h4>Results</h4>We included 9,687 patients. For those starting RDV administration in the complicat"],"journal":["Infection"],"pagination":["1033-1049"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9913009"],"repository":["biostudies-literature"],"pubmed_title":["Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study."],"pmcid":["PMC9913009"],"pubmed_authors":["Pilgram L","de Miranda SMN","Hellwig K","Appel KS","Stecher M","Vehreschild MJGT","Vom Dahl J","Spinner CD","Hertenstein B","Hower M","Jensen BO","Wille K","Ruethrich MM","Koll CEM","Hanses F","Haselberger M","Westhoff T","Vehreschild JJ"],"additional_accession":[]},"is_claimable":false,"name":"Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study.","description":"<h4>Objectives</h4>The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation.<h4>Methods</h4>SARS-CoV-2 infected patients between January 2020 and December 2021 treated with RDV were matched 1:1 to controls considering sociodemographics, comorbidities and clinical status. Multiple imputations were used to account for missing data. Effects on fatal outcome were estimated using uni- and multivariable Cox regression models.<h4>Results</h4>We included 9,687 patients. For those starting RDV administration in the complicat","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-04T13:08:23.454Z","creation":"2025-04-04T13:08:23.454Z"},"accession":"S-EPMC9913009","cross_references":{"pubmed":["36763285"],"doi":["10.1007/s15010-023-01994-0"]}}